Scrip Podcast Ep 5 April 2020: Analysis On Pharma In The Time Of COVID-19

Gilead is set to release pivotal data for its antiviral remdesivir. But will the drug really play a decisive role against coronavirus? Plus an interview with Carl Hansen, CEO of AbCellera, one of several companies racing to find an antibody drug which could provide ‘passive immunity’ against coronavirus while we await a vaccine. Plus analysis of the first quarter impact of the pandemic on biopharma business, and reasons to be cheerful during the lockdown. Hosted by Andrew McConaghie, Sarah Karlin-Smith and Kevin Grogan from the Scrip Pharma Intelligence team in the UK and Beijing.